Delivery Order HHSN261201200031I-HHSN26100008
Award Date 9/1/15
Potential Completion Date 8/31/21
Potential Value $813K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Tucson, AZ 85719, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
6
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Arizona, doing business as the Arizona Board of Regents. The $151,603.00 delivery order supports the "UNIVERSITY OF CALIFORNIA AT IRVINE CLINICAL TRIAL SUPPORT" effort under the Cancer Prevention Agent Development Program 2012-2017, a major NCI program focused on early-phase clinical cancer research. This contract does...
- This is a $580,503.00 delivery order award under the Cancer Prevention Agent Development Program 2012-2017 indefinite delivery contract issued by the National Cancer Institute, a component of the U.S. Department of Health and Human Services. The order was awarded to the University of Arizona, doing business as the Arizona Board of Regents, for research and development services to support core infrastructure for the agency's cancer prevention agent development efforts. The work will be...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Delivery Order contract to the University of Arizona, doing business as the Arizona Board of Regents, to provide core infrastructure support for the Cancer Prevention Agent Development Program. The $1,535,496.00 contract has a performance period ending on September 22, 2023 and does not utilize a set-aside designation. This Delivery Order is part of the larger Cancer Prevention Agent...
- This is a federal contract award from the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Arizona, a public research university and land grant institution, for a clinical study on the effects of combined aspirin and zileuton treatment on tobacco-related carcinogenesis biomarkers in current smokers. The $1,476,557 award falls under the Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle, and has...
- This is a federal contract award to the University of Arizona, doing business as the Arizona Board of Regents, by the National Cancer Institute (NCI). The $796,585.45 contract is for a clinical study of Avmacol, a product aimed at detoxifying tobacco carcinogens in heavy smokers. This award is part of the NCI's Cancer Prevention Agent Development Program, which funds early-phase clinical research. The contract is a delivery order under a master Indefinite Delivery/Indefinite Quantity (IDIQ)...
- This is a federal contract award to the University of Arizona, doing business as the Arizona Board of Regents, by the National Cancer Institute (NCI) under the Cancer Prevention Agent Development Program 2012-2017. The award has a ceiling value of $2,924,327.60 and is for research and development services related to the core infrastructure support for the NCI's cancer prevention agent development program's early phase clinical research. The contract is a delivery order and does not have a...
- This is a delivery order under the Cancer Prevention Agent Development Program 2012-2017 IDIQ contract, awarded by the National Cancer Institute to the University of Arizona for a value of $1,027,142.83. The contract is for the development of topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) grades 2-3, with a period of performance through September 15, 2023. The contract does not have a set-aside designation. The University of Arizona has subcontracted a portion of...
- The University of Arizona, doing business as the Arizona Board of Regents, has been awarded a $2,789,411.92 cost-type delivery order contract by the National Cancer Institute (NCI) to conduct a Phase II randomized, placebo-controlled clinical trial of the prostate cancer vaccine Prostvac (PSA-TRICOM) in patients with clinically localized prostate cancer undergoing active surveillance. This contract supports the NCI's Cancer Prevention Agent Development Program 2012-2017 and does not have a...
- This federal contract award, valued at $2,843,821, was issued by the National Cancer Institute to the University of Arizona, doing business as the Arizona Board of Regents, for a prospective Phase IIa clinical trial to assess the immunogenicity of a nonavalent prophylactic HPV vaccine using a prime and deferred-booster dosing schedule in 9-12 year old girls. The award is part of the Cancer Prevention Agent Development Program, which supports early-phase clinical trials. This is not a set-aside...
- This federal contract award, valued at $226,000.00, was issued by the Department of Health and Human Services National Institutes of Health National Institute of Environmental Health Sciences to the University of Arizona, doing business as the Arizona Board of Regents. The contract is for a "TAS TEXTING TEENS ABOUT WELLNESS & SKIN CANCER RESEACH PROJECT WITH NLM AND AND THE ARIZONA BOARD OF REGENTS, UNIVERSITY OF ARIZONA, ARIZONA CANCER CENTER" and has a completion date of July 14,...